In CML, TKIs are particularly effective in blocking the breakpoint cluster region (BCR) and Abelson (ABL) gene fusion TK, which is a key driver of the disease. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.